secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0000914475-25-000081
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine appoints Sanjay Keswani as CMO effective June 2; Roberts transitions to advisory role
--------------------------------------------------------------------------------

- Sanjay Keswani appointed CMO effective June 2, 2025; Eiry Roberts transitions to strategic advisory role after 7 years as CMO.
- Keswani brings >20 yrs pharma/biotech experience; formerly CEO of ImmunoBrain, SVP at Roche, VP at BMS.
- Roberts led INGREZZA expansion, crinecerfont approval as CRENESSITY, and Phase 2 studies for osavampator and NBI-1117568 now moving to registrational.
- Roberts' retirement was announced in July 2023; she remained until replacement onboarded; orderly succession.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000081/0000914475-25-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000081/nbix-20250402.htm
  HTML page:      https://secwatch.observer/filing/0000914475-25-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer